HomeFileStructural heart disease

Structural heart disease

Edge-to-Edge Tricuspid Valve Repair 3-Year Follow Up

Tricuspid regurgitation (TR) is associated to fatigue and peripheral edema, and medical treatment with diuretics has a...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral...

MATTERHORN: Edge-to-Edge Repair vs. Surgery for Secondary Mitral Valve Regurgitation

Frequently associated with hospitalization for cardiac failure and mortality, secondary mitral valve regurgitation (MR) is the most...

RESHAPE-HF2 Trial: Edge-to-Edge Repair in Secondary Mitral Valve Regurgitation vs. Complete Medical Treatment

Severe secondary Mitral Valve Regurgitation (MR) has been associated with increased hospitalization and mortality. Even though optimal...

¿What Should We Do About Significant Coronary Lesions in TAVR?

Aortic stenosis and coronary artery disease (CAD) share risk factors, which means significant lesions will coexist in...

ESC 2024 | RHEIA Trial: Transcatheter vs. Surgical Replacement in Women

The RHEIA trial is the first randomized, women-exclusive international study aimed to assess the safety and efficacy...

ESC 2024 | POPular PAUSE TAVI: Continuation vs. Discontinuation of Oral Anticoagulant Therapy During TAVI

Due to their advanced age and comorbidities, many patients with severe aortic stenosis scheduled for transcatheter aortic...

ESC 2024 | NOTION 3 Trial: Percutaneous Coronary Intervention in Patients with a Planned Transcatheter Aortic Valve Implantation

The relationship between aortic stenosis and valve disease is well established, with revascularization rates in this population...